While anti-cancer therapies, including chemotherapy, immunotherapy, radiotherapy, and targeted therapy, are constantly advancing, cardiovascular toxicity has become a major challenge for cardiologists and oncologists. This has led to an increasing demand of cardio-oncology units in Europe and a growing interest of clinicians and researchers. The Heart Failure 2019 meeting of the Heart Failure Association of the European Society of Cardiology in Athens has therefore created a scientific programme that included four dedicated sessions on the topic along with several additional lectures. The major points that were discussed at the congress included the implementation and delivery of a cardio-oncology service, the collaboration among cardio-oncology experts, and the risk stratification, prevention, and early recognition of cardiotoxicity. Furthermore, sessions addressed the numerous different anti-cancer therapies associated with cardiotoxic effects and provided guidance on how to treat cancer patients who develop cardiovascular disease before, during, and after treatment.

1st Department of Medicine Cardioangiology Faculty of Medicine University Hospital Hradec Králové Czech Republic

Comprehensive Heart Failure Center University Clinic Würzburg Würzburg Germany

Department of Cardiology and Pneumology Heart Center Göttingen German Center for Cardiovascular Medicine University of Göttingen Medical Center Georg August University Göttingen Germany

Department of Cardiology Cardio Oncology Clinic Heart Failure Unit Athens University Hospital 'Attikon' National and Kapodistrian University of Athens Athens Greece

Department of Cardiology Lariboisière Hospital and U942 INSERM BIOCANVAS Paris University Paris France

Department of Cardiology Medical University of Vienna Vienna Austria

Department of Cardiology University of Groningen University Medical Center Groningen Groningen The Netherlands

Department of Community Cardiology Clalit Health Fund and Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

Department of Internal Medicine American University of Beirut Medical Center Beirut Lebanon

Department of Translational Medical Sciences and Interdepartmental Center for Clinical and Translational Sciences Federico 2 University Naples Italy

Division of Cardiology and Metabolism Department of Cardiology Charité and Berlin Institute of Health Center for Regenerative Therapies partner site Berlin and Department of Cardiology Charité Campus Benjamin Franklin Berlin Germany

Faculty of Medicine and Heart Failure Center Belgrade University Medical Center University of Belgrade Belgrade Serbia

IRCCS San Raffaele Rome Italy

Royal Brompton Hospital and Imperial College London London UK

Sechenov Medical University Moscow Russia

University of Cyprus Medical School Nicosia Cyprus

Zobrazit více v PubMed

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOSCAN 2012. Int J Cancer 2015; 136: E359–E386. PubMed

de Moor JS, Mariotto AB, Parry C, Alfano CM, Padgett L, Kent EE, Forsythe L, Scoppa S, Hachey M, Rowland JH. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev 2013; 22: 561–570. PubMed PMC

Na SY, Sung JY, Chang JH, Kim S, Lee HH, Park YH, Chung W, Oh KH, Jung JY. Chronic kidney disease in cancer patients: an independent predictor of cancer‐specific mortality. Am J Nephrol 2011; 33: 121–130. PubMed

Stengel B. Chronic kidney disease and cancer: a troubling connection. J Nephrol 2010; 23: 253–262. PubMed PMC

Hampel PJ, Chaffee KG, King RL, Simonetto D, Larson MC, Achenbach S, Call TG, Ding W, Kenderian SS, Leis JF, Chanan‐Khan AA, Bowen DA, Conte MJ, Schwager SM, Hanson CA, Slager SL, Kay NE, Shanafelt TD, Parikh SA. Liver dysfunction in chronic lymphocytic leukemia: prevalence, outcomes, and pathological findings. Am J Hematol 2017; 92: 1362–1369. PubMed PMC

Maor Y, Malnick S. Liver injury induced by anticancer chemotherapy and radiation therapy. Int J Hepatol 2013; 2013: 815105. PubMed PMC

Boussios S, Pentheroudakis G, Katsanos K, Pavlidis N. Systemic treatment‐induced gastrointestinal toxicity: incidence, clinical presentation and management. Ann Gastroenterol 2012; 25: 106–118. PubMed PMC

Gibson RJ, Keefe DM, Lalla RV, Bateman E, Blijlevens N, Fijlstra M, King EE, Stringer AM, van der Velden WJ, Yazbeck R, Elad S. Bowen JM; Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer 2013; 21: 313–326. PubMed

Rodgers GM, Becker PS, Blinder M, Cella D, Chanan‐Khan A, Cleeland C, Coccia PF, Djulbegovic B, Gilreath JA, Kraut EH, Matulonis UA, Millenson MM, Reinke D, Rosenthal J, Schwartz RN, Soff G, Stein RS, Vlahovic G, Weir AB. Cancer‐ and chemotherapy‐induced anemia. J Natl Compr Canc Netw 2012; 10: 628–653. PubMed

Gilreath JA, Stenehjem DD, Rodgers GM. Diagnosis and treatment of cancer‐related anemia. Am J Hematol 2014; 89: 203–212. PubMed

Neefjes ECW, van den Hurk RM, Blauwhoff‐Buskermolen S, van der Vorst MJDL, Becker‐Commissaris A, de van der Schueren MAE, Buffart LM, Verheul HMW. Muscle mass as a target to reduce fatigue in patients with advanced cancer. J Cachexia Sarcopenia Muscle 2017; 8: 623–629. PubMed PMC

Bohlen J, McLaughlin SL, Hazard‐Jenkins H, Infante AM, Montgomery C, Davis M, Pistilli EE. Dysregulation of metabolic‐associated pathways in muscle of breast cancer patients: preclinical evaluation of interleukin‐15 targeting fatigue. J Cachexia Sarcopenia Muscle 2018; 9: 701–714. PubMed PMC

Rolston KV. Infections in cancer patients with solid tumors: a review. Infect Dis Ther 2017; 6: 69–83. PubMed PMC

Cole CL, Kleckner IR, Jatoi A, Schwarz EM, Dunne RF. The role of systemic inflammation in cancer‐associated muscle wasting and rationale for exercise as a therapeutic intervention. JCSM Clin Rep 2018; 3. PubMed PMC

Molfino A, Iannace A, Colaiacomo MC, Farcomeni A, Emiliani A, Gualdi G, Laviano A, Rossi FF. Cancer anorexia: hypothalamic activity and its association with inflammation and appetite‐regulating peptides in lung cancer. J Cachexia Sarcopenia Muscle 2017; 8: 40–47. PubMed PMC

Rodriguez AM, Braverman J, Aggarwal D, Friend J, Duus E. The experience of weight loss and its associated burden in patients with non‐small cell lung cancer: results of an online survey. JCSM Clin Rep 2017; 2.

Lena A, Coats AJS, Anker MS. Metabolic disorders in heart failure and cancer. ESC Heart Fail 2018; 5: 1092–1098. PubMed PMC

Choi MH, Oh SN, Lee IK, Oh ST, Won DD. Sarcopenia is negatively associated with long‐term outcoes in locally advanced rectal cancer. J Cachexia Sarcopenia Muscle 2018; 9: 53–59. PubMed PMC

Roberto A, Deandrea S, Greco MT, Corli O, Negri E, Pizzuto M, Ruggeri F. Prevalence of neuropathic pain in cancer patients: pooled estimates from a systematic review of published literature and results from a survey conducted in 50 Italian palliative care centers. J Pain Symptom Manage 2016; 51: 1091–1102.e4. PubMed

Nijs J, Leysen L, Adriaenssens N, Aguilar Ferrándiz ME, Devoogdt N, Tassenoy A, Ickmans K, Goubert D, van Wilgen CP, Wijma AJ, Kuppens K, Hoelen W, Hoelen A, Moloney N, Meeus M. Pain following cancer treatment: guidelines for the clinical classification of predominant neuropathic, nociceptive and central sensitization pain. Acta Oncol 2016; 55: 659–663. PubMed

Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: Part 1. J Am Coll Cardiol 2017; 70: 2536–2551. PubMed PMC

Anker MS, Lena A, Hadzibegovic S, Belenkov Y, Bergler‐Klein J, Boer RA, Cohen‐Solal A, Farmakis D, Haehling S, López‐Fernández T, Pudil R, Suter T, Tocchetti CG, Lyon AR. and for the Heart Failure Association Cardio‐Oncology Study Group of the European Society of Cardiology. Modern‐day cardio‐oncology: a report from the ‘Heart Failure and World Congress on Acute Heart Failure 2018’. ESC Heart Fail 2018; 5: 1083–1091. PubMed PMC

Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 2768–2801. PubMed

Fornaro A, Olivotto I, Rigacci L, Ciaccheri M, Tomberli B, Ferrantini C, Coppini R, Girolami F, Mazzarotto F, Chiostri M, Milli M, Marchionni N, Castelli G. Comparison of long‐term outcome in anthracycline‐related versus idiopathic dilated cardiomyopathy: a single centre experience. Eur J Heart Fail 2018; 20: 898–906. PubMed

Mamas MA, Sperrin M, Watson MC, Coutts A, Wilde K, Burton C, Kadam UT, Kwok CS, Clark AB, Murchie P, Buchan I, Hannaford PC, Myint PK. Do patients have worse outcomes in heart failure than in cancer? A primary care‐based cohort study with 10‐year follow‐up in Scotland. Eur J Heart Fail 2017; 19: 1095–1104. PubMed

Kreusser MM, Tschierschke R, Beckendorf J, Baxmann T, Frankenstein L, Dösch AO, Schultz JH, Giannitsis E, Pleger ST, Ruhparwar A, Karck M, Katus HA, Raake PW. The need for dedicated advanced heart failure units to optimize heart failure care: impact of optimized advanced heart failure unit care on heart transplant outcome in high‐risk patients. ESC Heart Fail 2018; 5: 1108–1117. PubMed PMC

Harrison JM, Davis MA, Barton DL, Janz NK, Pressler SJ, Friese CR. Functional status and quality of life among breast cancer survivors with heart failure: results of the Medicare Health Outcomes Survey. Support Care Cancer 2017; 25: 2463–2473. PubMed

Saitoh M, Dos Santos MR, Emami A, Ishida J, Ebner N, Valentova M, Bekfani T, Sandek A, Lainscak M, Doehner W, Anker SD, von Haehling S. Anorexia, functional capacity, and clinical outcome in patients with chronic heart failure: results from the Studies Investigating Co‐morbidities Aggravating Heart Failure (SICA‐HF). ESC Heart Fail 2017; 4: 448–457. PubMed PMC

Riley JP, Beattie JM. Palliative care in heart failure: facts and numbers. ESC Heart Fail 2017; 4: 81–87. PubMed PMC

Costanzo MR, Ronco C, Abraham WT, Agostoni P, Barasch J, Fonarow GC, Gottlieb SS, Jaski BE, Kazory A, Levin AP, Levin HR, Marenzi G, Mullens W, Negoianu D, Redfield MM, Tang WHW, Testani JM, Voors AA. Extracorporeal ultrafiltration for fluid overload in heart failure: current status and prospects for further research. J Am Coll Cardiol 2017; 69: 2428–2445. PubMed PMC

von Haehling S. Co‐morbidities in heart failure beginning to sprout‐and no end in sight? Eur J Heart Fail 2017; 19: 1566–1568. PubMed

Platz E, Jhund PS, Claggett BL, Pfeffer MA, Swedberg K, Granger CB, Yusuf S, Solomon SD, McMurray JJ. Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality. Eur J Heart Fail 2018; 20: 295–303. PubMed PMC

Salem K, ElKhateeb O. Gender‐adjusted and age‐adjusted economic burden of congestive heart failure: cost and disability‐adjusted life‐year analysis. ESC Heart Fail 2017; 4: 259–265. PubMed PMC

Hess CN, Roe MT. Treatment of coronary artery disease in cancer survivors: an emerging challenge. Coron Artery Dis 2017; 28: 1–2. PubMed

Farmakis D, Parissis J, Filippatos G. Insights into onco‐cardiology: atrial fibrillation in cancer. J Am Coll Cardiol 2014; 63: 945–953. PubMed

Colt JS, Schwartz K, Graubard BI, Davis D, Ruterbusch J, DiGaetano R, Purdue M, Rothman N, Wacholder S, Chow WH. Hypertension and risk of renal cell carcinoma among white and black Americans. Epidemiology 2011; 134: 2269–2277. PubMed PMC

Di Nisio M, Ferrante N, Feragalli B, De Tursi M, Iacobelli S, Cuccurullo F, Porreca E. Arterial thrombosis in ambulatory cancer patients treated with chemotherapy. Thromb Res 2011; 127: 382–383. PubMed

Hering D, Faber L, Horstkotte D. Echocardiographic features of radiation‐associated valvular disease. Am J Cardiol 2003; 92: 226–230. PubMed

Limsuwan A, Pakakasama S, Rochanawutanon M, Hong‐eng S. Pulmonary arterial hypertension after childhood cancer therapy and bone marrow transplantation. Cardiology 2006; 105: 188–194. PubMed

Plummer C, Henderson RD. O´Sullivan JD and Read SJ. Ischemic stroke and transient ischemic attack after head and neck radiotherapy: a review. Stroke 2011; 42: 2410–2418. PubMed

Valent P, Hadzijusufovic E, Schernthaner GH, Wolf D, Rea D, le Coutre P. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood 2015; 125: 901–906. PubMed

Chow EJ, Leger KJ, Bhatt NS, Mulrooney DA, Ross CJ, Aggarwal S, Bansal N, Ehrhardt MJ, Armenian SH, Scott JM, Hong B. Paediatric cardio‐oncology: epidemiology, screening, prevention, and treatment. Cardiovasc Res 2019; 115: 922–934. PubMed PMC

Serrano C, Cortes J, De Mattos‐Arruda L, Bellet M, Gomez P, Saura C, Perez J, Vidal M, Munoz‐Couselo E, Carreras MJ, Sanchez‐Olle G, Tabernero J, Baselga J, Di Cosimo S. Trastuzumab‐related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol 2012; 23: 897–902. PubMed

Anker MS, von Haehling S, Landmesser U, Coats AJS, Anker SD. Cancer and heart failure‐more than meets the eye: common risk factors and co‐morbidities. Eur J Heart Fail 2018; 20: 1382–1384. PubMed

Lenneman CG, Sawyer DB. Cardio‐oncology: an update on cardiotoxicity of cancer‐related treatment. Circ Res 2016; 118: 1008–1020. PubMed

Farmakis D, Keramida K, Filippatos G. How to build a cardio‐oncology service? Eur J Heart Fail 2018; 20: 1732–1734. PubMed

Karlstaedt A, Zhang X, Vitrac H, Harmancey R, Vasquez H, Wang JH, Goodell MA, Taegtmeyer H. Oncometabolite d‐2‐hydroxyglutarate impairs α‐ketoglutarate dehydrogenase and contractile function in rodent heart. Proc Natl Acad Sci U S A 2016; 113: 10436–10441. PubMed PMC

Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869–2879. PubMed

Boerman LM, Maass SWMC, van der Meer P, Gietema JA, Maduro JH, Hummel YM, Berger MY, de Boeck GH, Berendsen AJ. Long‐term outcome of cardiac function in a population‐based cohort of breast cancer survivors: A cross‐sectional study. Eur J Cancer 2017; 81: 56–65. PubMed

Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation 2016; 133: 1104–1114. PubMed PMC

Meijers WC, de Boer RA. Common risk factors for heart failure and cancer. Cardiovasc Res 2019; 115: 844–853. PubMed PMC

de Boer RA, Meijers WC, van der Meer P, van Veldhuisen DJ. Cancer and heart disease: associations and relations. Eur J Heart Fail. 2019. https://doi.org/10.1002/ejhf.1539 PubMed PMC

Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida‐Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ, CANTOS Trial Group . Antinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377: 1119–1131. PubMed

Chabner BA, Nabel CS. Canakinumab and lung cancer: intriguing, but is it real? Oncologist 2018; 23: 637–638. PubMed PMC

Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, CANTOS Trial Group . Effect of interleukin‐1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double‐blind, placebo‐controlled trial. Lancet 2017; 390: 1833–1842. PubMed

Cramer L, Hildebrandt B, Kung T, Wichmann K, Springer J, Doehner W, Sandek A, Valentova M, Stojakovic T, Scharnagl H, Riess H, Anker SD, von Haehling S. Cardiovascular function and predictors of exercise capacity in patients with colorectal cancer. J Am Coll Cardiol 2014; 64: 1310–1319. PubMed

Anker MS, Ebner N, Hildebrandt B, Springer J, Sinn M, Riess H, Anker SD, Landmesser U, Haverkamp W, von Haehling S. Resting heart rate is an independent predictor of death in patients with colorectal, pancreatic, and non‐small cell lung cancer: results of a prospective cardiovascular long‐term study. Eur J Heart Fail 2016; 18: 1524–1534. PubMed

Lee DH, Park S, Lim SM, Lee MK, Giovannucci EL, Kim JH, Kim SI, Jeon JY. Resting heart rate as a prognostic factor for mortality in patients with breast cancer. Breast Cancer Res Treat 2016; 159: 375–384. PubMed

Park J, Kim JH, Park Y, Park SJ, Cheon JH, Kim WH, Park JS, Jeon JY, Kim TI. Resting heart rate is an independent predictor of advanced colorectal adenoma recurrence. PLoS One 2018; 13: e0193753. PubMed PMC

van Bilsen M, Patel HC, Bauersachs J, Böhm M, Borggrefe M, Brutsaert D, Coats AJS, de Boer RA, de Keulenaer GW, Filippatos GS, Floras J, Grassi G, Jankowska EA, Kornet L, Lunde IG, Maack C, Mahfoud F, Pollesello P, Ponikowski P, Ruschitzka F, Sabbah HN, Schultz HD, Seferovic P, Slart RHJA, Taggart P, Tocchetti CG, Van Laake LW, Zannad F, Heymans S, Lyon AR. The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2017; 19: 1361–1378. PubMed

López‐Fernández T, Martín García A, Santaballa Beltrán A, Montero Luis Á, García Sanz R, Mazón Ramos P, Velasco Del Castillo S, López de Sá Areses E, Barreiro‐Pérez M, Hinojar Baydes R, Pérez de Isla L, Valbuena López SC, Dalmau González‐Gallarza R, Calvo‐Iglesias F, González Ferrer JJ, Castro Fernández A, González‐Caballero E, Mitroi C, Arenas M, Virizuela Echaburu JA, Marco Vera P, Íñiguez Romo A, Zamorano JL, Plana Gómez JC, López Sendón Henchel JL. Cardio‐onco‐hematology in clinical practice. Position paper and recommendations. Rev Esp Cardiol (Engl Ed) 2017; 70: 474–486. PubMed

Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popović ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol 2013; 61: 77–84. PubMed

Tamborini G, Piazzese C, Lang RM, Muratori M, Chiorino E, Mapelli M, Fusini L, Ali SG, Gripari P, Pontone G, Andreini D, Pepi M. Feasibility and accuracy of automated software for transthoracic three‐dimensional left ventricular volume and function analysis: comparisons with two‐dimensional echocardiography, three‐dimensional transthoracic manual method, and cardiac magnetic resonance imaging. J Am Soc Echocardiogr 2017; 30: 1049–1058. PubMed

Zhang KW, Finkelman BS, Gulati G, Narayan HK, Upshaw J, Narayan V, Plappert T, Englefield V, Smith AM, Zhang C, Hundley WG, Ky B. Abnormalities in 3‐dimensional left ventricular mechanics with anthracycline chemotherapy are associated with systolic and diastolic dysfunction. JACC Cardiovasc Imaging 2018; 11: 1059–1068. PubMed PMC

Negishi T, Thavendiranathan P. Negishi K and Marwick TH; SUCCOUR investigators. Rationale and design of the strain surveillance of chemotherapy for improving cardiovascular outcomes: The SUCCOUR trial. JACC Cardiovasc Imaging 2018; 11: 1098–1105. PubMed

Lopez‐Fernandez T, Thavendiranathan P. Emerging cardiac imaging modalities for the early detection of cardiotoxicity due to anticancer therapies. Rev Esp Cardiol 2017; 70: 487–495. PubMed

Keramida K, Farmakis D, Bingcang J, Sulemane S, Sutherland S, Bingcang RA, Ramachandran K, Tzavara C, Charalampopoulos G, Filippiadis D, Kouris N, Nihoyannopoulos P. Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients. Eur J Heart Fail 2019; 21: 529–535. PubMed

Harries I, Biglino G, Baritussio A, De Garate E, Dastidar A, Plana J and Bucciarelli‐Ducci C4 . Long term cardiovascular magnetic resonance phenotyping of anthracycline cardiomyopathy. Int J Cardiol. 2019. pii: S0167‐5273(19)30293‐1. PubMed

Cardinale D, Biasillo G, Salvatici M, Sandri MT, Cipolla CM. Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy. Expert Rev Mol Diagn 2017; 17: 245–256. PubMed

Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer‐Crosbie M, Ganame J, Sebag IA, Angler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, DeCara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalhaes A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P. Expert consensus for multimodality imaging evaluation od adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014; 27: 911–939. PubMed

Sandri MT, Salvatici M, Cardinale D, Zorzino L, Passerini R, Lentati P, Leon M, Civell M, Martinelli G, Cipolla CM. N‐terminal pro‐B‐type natriuretic peptide after high‐dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem 2005; 51: 1405–1410. PubMed

Ky B, Putt M, Sawaya H, French B, Januzzi JL Jr, Sebag IA, Plana JC, Cohen V, Banchs J, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer‐Crosbie M. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 2014; 63: 809–816. PubMed PMC

Todorova VK, Makhoul I, Wei J, Klimberg VS. Circulating miRNA profiles of doxorubicin‐induced cardiotoxicity in breast cancer patients. Ann Clin Lab Sci 2017; 47: 116–119. PubMed

Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: cardio‐oncology. Mayo Clin Proc 2014; 89: 1287–1306. PubMed PMC

Lotrionte M, Biondi‐Zoccai G, Abbate A, Lanzetta G, D'Ascenzo F, Malavasi V, Peruzzi M, Frati G, Palazzoni G. Review and meta‐analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol 2013; 112: 1980–1984. PubMed

Cavarretta E, Mastroiacovo G, Lupieri A, Frati G, Peruzzi M. The positive effects of exercise in chemotherapy‐related cardiomyopathy. Adv Exp Med Biol 2017; 1000: 103–129. PubMed

Howden EJ, Bigaran A, Beaudry R, Fraser S, Selig S, Foulkes S, Antill Y, Nightingale S, Loi S, Haykowsky MJ, La Gerche A. Exercise as a diagnostic and theapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients. Eur J Prev Cardiol 2019; 26: 305–315. PubMed

Gilchrist SC, Barac A, Ades PA, Alfano CM, Franklin BA, Jones LW, La Gerche A, Ligibel JA, Lopez G, Madan K, Oeffinger KC, Salamone J, Scott JM, Squires RW, Thomas RJ, Treat‐Jacobson DJ, Wright JS, American Heart Association Exercise, Cardiac Rehabilitation, and Secondary Prevention Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Peripheral Vascular Disease . Cardio‐oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association. Circulation 2019: 139:e997–e1012. PubMed PMC

Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, Cohen V, Banchs J, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer‐Crosbie M. Asssessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes and trastuzumab. Circ Cardiovasc Imaging 2012; 5: 596–603. PubMed PMC

Mertens AC, Yasui Y, Neglia JP, Potter JD, Nesbit ME Jr, Ruccione K, Smithson WA, Robison LL. Late mortality experience in five‐year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 2001; 19: 3163–3172. PubMed

Lenihan DJ, Cardinale DM. Late cardiac effects of cancer treatment. J Clin Oncol 2012; 30: 3657–3664. PubMed

Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano G, Fiorentini C, Cipolla CM. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015; 131: 1981–1988. PubMed

Lancellotti P, Suter TM, Lopez‐Fernandez T, Galderisi M, Lyon AR, Van der Meer P, Cohen Solal A, Zamorano JL, Jerusalem G, Moonen M, Aboyans V, Bax JJ, Asteggiano R. Cardio‐oncology services: rationale, organization, and implementation: a report from the ESC cardio‐oncology council. Eur Heart J 2019; 40: 1756–1763. PubMed

Pareek N, Cevallos J, Moliner P, Shah M, Tan LL, Chambers V, Baksi AJ, Khattar RS, Sharma R, Rosen SD, Lyon AR. Activity and outcomes of a cardio‐oncology service in the United Kingdom‐a five‐year experience. Eur J Heart Fail 2018; 20: 1721–1731. PubMed

Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio‐oncology and cardio‐oncological prevention. J Natl Cancer Inst 2010; 102: 14–25. PubMed PMC

Sarocchi M, Arboscello E, Ghigliotti G, Murialdo R, Bighin C, Gualandi F, Sicbaldi V, Balbi M, Brunelli C, Spallarossa P. Ivabradine in cancer treatment‐related left ventricular dysfunction. Chemotherapy 2018; 63: 315–320. PubMed

Mertens P, Belien H, Dupont M, Vandervoort P, Mullens W. The reverse remodelling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. Cardiovasc Therapy 2018; 36: e12435. PubMed

Heart Rhythm Congress 2019. S‐LBCT02‐04.

https://clinicaltrials.gov/ct2/show/NCT02164721

Hodi FS, Chiarion‐Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hill A, Hogg D, Marquez‐Rodas I, Jiang J, Rizzo J, Larkin J, Wolchok JD. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4‐year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 2018; 19: 1480–1492. PubMed

Rizvi NA, Mazieres J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez‐Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS. Activity and safety of nivolumab, an anti‐PD‐1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non‐small‐cell lung cancer (CheckMate 063): a phase 2, single‐arm trial. Lancet Oncol 2015; 16: 257–265. PubMed PMC

Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, Lyon AR, Padera RF, Johnson DB, Moslehi J. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res 2019; 115: 854–868. PubMed PMC

Moslehi JJ, Salem JE, Sosman JA, Lebrun‐Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor‐associated myocarditis. Lancet 2018; 391: 933. PubMed PMC

Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol 2018; 19: 447–458. PubMed

Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, Lyon AR, Padera RF, Johnson DB, Moslehi J. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res 2019; 115: 854–868. PubMed PMC

Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N, Honjo T. Autoimmune dilated cardiomyopathy in PD‐1 receptor‐deficient mice. Science (New York, NY) 2001; 291: 319–322. PubMed

Varricchi G, Marone G, Mercurio V, Galdiero MR, Bonaduce D, Tocchetti CG. Immune checkpoint inhibitors and cardiac toxicity: an emerging issue. Curr Med Chem 2018; 25: 1327–1339. PubMed

Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015; 348: 62–68. PubMed PMC

Ponzetta A, Carriero R, Carnevale S, Barbagallo M, Molgora M, Perucchini C, Magrini E, Gianni F, Kunderfranco P, Polentarutti N, Pasqualini F, Di Marco S, Supino D, Peano C, Cananzi F, Colombo P, Pilotti S, Alomar SY, Bonavita E, Galdiero MR, Garlanda C, Mantovani A, Jaillon S. Neutrophils driving unconventional T cells mediate resistance against murine sarcomas and selected human tumors. Cell 2019; 178: 346–360.e24. PubMed PMC

Li M, Sala V, De Santis MC, Cimino J, Cappello P, Pianca N, Di Bona A, Margaria JP, Martini M, Lazzarini E, Pirozzi F, Rossi L, Franco I, Bornbaum J, Heger J, Rohrbach S, Perino A, Tocchetti CG, Lima BHF, Teixeira MM, Porporato PE, Schulz R, Angelini A, Sandri M, Ameri P, Sciarretta S, Lima‐Júnior RCP, Mongillo M, Zaglia T, Morello F, Novelli F, Hirsch E, Ghigo A. Phosphoinositide 3‐kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth. Circulation 2018; 138: 696–711. PubMed

Segers VFM, Brutsaert DL, DeKeulenaer GW. Cardiac remodelling: endothelial cells have more to say than just no. Front Phsysiol 2018; 9: 382. PubMed PMC

Kivelä R, Hemanthakumar KA, Vaparanta K, Robciuc M, Izumiya Y, Kidoya H, Takakura N, Peng X, Sawyer DB, Elenius K, Walsh K, Alitalo K. Endothelial cells regulate physiological cardiomyocyte growth via VEGFR2‐mediated paracrine signaling. Circulation 2019; 139: 2570–2584. PubMed PMC

Bertero E, Canepa M, Maack C, Ameri P. Linking heart failure to cancer. Circulation 2018; 138: 735–742. PubMed